TY - JOUR
T1 - Unaltered cerebral blood flow during hypoglycemic activation of the sympathochromaffin system in humans
AU - Powers, W. J.
AU - Boyle, P. J.
AU - Hirsch, I. B.
AU - Cryer, P. E.
PY - 1993
Y1 - 1993
N2 - To determine if increases in plasma epinephrine and norepinephrine caused by hypoglycemia are associated with increments in cerebral blood flow (CBF), we measured CBF with positron emission tomography in normal humans at ambient fasting arterial plasma glucose levels and at clamped plasma glucose levels of 5.3, 3.5, and 2.8 mmol/l using the hyperinsulinemic, stepped hypoglycemic clamp technique. Despite significant increases in plasma epinephrine to 7,340 ± 350 (SE) pmol/l and in plasma norepinephrine to 3.32 ± 0.35 nmol/l, mean hemispheric CBF (41 ± 1, 49 ± 1, 48 ± 2, and 51 ± 3 ml · 100 g-1 · min-1) remained constant at the ambient (5.2), 5.3, 3.5, and 2.8 mmol/l glycemic levels, respectively. Furthermore, there was no correlation between CBF and either plasma epinephrine levels ranging from 160 to 10,580 pmol/l or plasma norepinephrine levels ranging from 0.56 to 5.10 nmol/l. Failure to demonstrate any dose-response relationship between plasma catecholamine levels and CBF argues against their primary role in cerebrovascular control during hypoglycemia.
AB - To determine if increases in plasma epinephrine and norepinephrine caused by hypoglycemia are associated with increments in cerebral blood flow (CBF), we measured CBF with positron emission tomography in normal humans at ambient fasting arterial plasma glucose levels and at clamped plasma glucose levels of 5.3, 3.5, and 2.8 mmol/l using the hyperinsulinemic, stepped hypoglycemic clamp technique. Despite significant increases in plasma epinephrine to 7,340 ± 350 (SE) pmol/l and in plasma norepinephrine to 3.32 ± 0.35 nmol/l, mean hemispheric CBF (41 ± 1, 49 ± 1, 48 ± 2, and 51 ± 3 ml · 100 g-1 · min-1) remained constant at the ambient (5.2), 5.3, 3.5, and 2.8 mmol/l glycemic levels, respectively. Furthermore, there was no correlation between CBF and either plasma epinephrine levels ranging from 160 to 10,580 pmol/l or plasma norepinephrine levels ranging from 0.56 to 5.10 nmol/l. Failure to demonstrate any dose-response relationship between plasma catecholamine levels and CBF argues against their primary role in cerebrovascular control during hypoglycemia.
KW - epinephrine
KW - glycemic thresholds during hypoglycemia
KW - hypoglycemia
KW - norepinephrine
UR - http://www.scopus.com/inward/record.url?scp=0027504525&partnerID=8YFLogxK
U2 - 10.1152/ajpregu.1993.265.4.r883
DO - 10.1152/ajpregu.1993.265.4.r883
M3 - Article
C2 - 8238461
AN - SCOPUS:0027504525
SN - 0002-9513
VL - 265
SP - R883-R887
JO - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
JF - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
IS - 4 34-4
ER -